<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6DC31837-4293-4838-972E-B70F4401FDE0"><gtr:id>6DC31837-4293-4838-972E-B70F4401FDE0</gtr:id><gtr:firstName>Heiner</gtr:firstName><gtr:surname>Grosskurth</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/96D43A36-8970-46E6-8DF4-0FA40E944EFC"><gtr:id>96D43A36-8970-46E6-8DF4-0FA40E944EFC</gtr:id><gtr:firstName>Paula</gtr:firstName><gtr:surname>Munderi</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_EX_UU_G0902150"><gtr:id>25DFC7F3-8DCF-4C3F-8165-CA50847F9060</gtr:id><gtr:title>Safety of discontinuing Cotrimoxazole Prophylaxis among African adults on ART. A randomised controlled trial</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MC_EX_UU_G0902150</gtr:grantReference><gtr:abstractText>atients with HIV infection often have severe damage to the body?s immune system and are at risk of various other infections (so called opportunistic infections) that may cause disease and death. Daily intake of the antinfective medication: cotrimoxazole (CTX) has been shown to be highly effective in reducing the frequency of these infectious complications of HIV disease. This prophylactic treatment with cotrimoxazole has therefore become standard practice for HIV infected patients. In industrialised countries, after the introduction of antiretroviral (ARV) treatments for HIV infection, studies showed that the additional prophylaxis with cotrimoxazole could safely be discontinued once patients showed evidence of restoration of their immune function. For some years now, many HIV infected patients in Africa have also started to receive antiretroviral treatments. ARVs help to restore a person?s immune system (although they cannot cure a person from HIV infection) and the provision of ARVs has changed the health of thousands of HIV infected people and dramatically reduced the death rate among those who take them. It may also be possible to discontinue CTX prophylaxis among patients whose immune system is working well again, but no studies have demonstrated the safety of this practice in Africa. Since ARV treatment is lifelong, it would be desirable; in order to reduce pill burden, reduce the risk of possible treatment side effects and contribute to better ARV treatment adherence and reduction of treatment costs. The planned study in Uganda will address this important question among African patients by investigating whether patients who are responding well to ARV treatment can discontinue prophylactic treatment with CTX without a substantially higher risk of becoming ill.</gtr:abstractText><gtr:technicalSummary>Cotrimoxazole (CTX) is a broad spectrum antimicrobial medication that is widely used as primary and secondary prophylaxis against opportunistic infections among HIV infected individuals. On the other hand, treatment of HIV infection with antiretroviral drugs permits restoration of the immune system with a resultant reduction in susceptibility to many of the opportunistic infections to which people with HIV are prone. Research done in industrialised countries has shown that it is not necessary to continue prophylactic treatment with CTX prophylaxis in patients on antiretroviral therapy (ART); and it is standard practice in industrialised countries to discontinue prophylactic treatment with CTX once immune restoration to a CD4 count of 200 cells/mm3 has been documented. In Africa, where there is a different spectrum of opportunistic infections among HIV infected patients, but where there is also increasing access to ART for HIV infected patients, there have been no controlled studies done on whether or not this additional prophylactic treatment with CTX can safely be discontinued once patients are stable on ART. Clinicians in Africa are uncertain about the safety of discontinuing CTX, yet continued indefinite administration of CTX for has the potential disadvantages of a high pill burden, possibility of side effects and increased costs. It is therefore important to establish in a controlled trial, whether CTX prophylaxis can be safely discontinued once patients on ART have regained their immune competence. The proposed non-inferiority trial will investigate the safety of stopping CTX medication among HIV infected patients who are also on ART, once they have achieved a CD4 count level of 250 cells/mm3 and above. HIV infected adults receiving both ART and CTX will be randomised to either continue with their combined medication (control group), or to receive their current ART plus CTX placebo (experimental group). About 2000 patients will be recruited in total at two study clinics of the MRC Uganda Research Unit on AIDS. They will be followed 3-monthly intervals for a median of 2 years and whenever ill. The primary outcome measure will be the incidence of serious CTX preventable clinical events and side effects of CTX. Secondary outcome measures will include the incidence of all clinical events including malaria episodes, mean change in CD4 count and other haematological parameters after 12 months on the trial, time to failure of ART, serious adverse events and compliance with ART regimens, trial drug regimens and use of insecticide- treated mosquito nets.</gtr:technicalSummary><gtr:fund><gtr:end>2014-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>0</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>36000</gtr:amountPounds><gtr:country>Uganda, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Training budget of the MRC Uganda Research Unit on AIDS - for PhD research of Dr Ronnie Kasirye</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>MRC/UVRI Uganda Research Unit on AIDS</gtr:fundingOrg><gtr:id>8DC5A601-2AC0-47F7-84F9-096412340E24</gtr:id><gtr:outcomeId>58c6b5085c3074.49916033</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4284A99E-8549-41E5-9013-9A585BE130E6</gtr:id><gtr:title>Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy: a randomised, placebo-controlled study.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77ddb32c61314a52229bd93344688de0"><gtr:id>77ddb32c61314a52229bd93344688de0</gtr:id><gtr:otherNames>Kasirye RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56d5df1cb20c88.30678227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A125E093-6384-4B56-9CD7-C3A5845F1E50</gtr:id><gtr:title>Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP trial): Design.</gtr:title><gtr:parentPublicationTitle>Contemporary clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/564ccdc3542d008364a7e56476c9013d"><gtr:id>564ccdc3542d008364a7e56476c9013d</gtr:id><gtr:otherNames>Anywaine Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1551-7144</gtr:issn><gtr:outcomeId>56d5e0a1369794.63782405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F80F80F5-5624-4726-B139-4E89E3FD968E</gtr:id><gtr:title>Is It Safe to Stop Cotrimoxazole in Adults on ART: COSTOP, a Non-inferiority RCT</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/209dc6a04f521377c3617f5457c4355c"><gtr:id>209dc6a04f521377c3617f5457c4355c</gtr:id><gtr:otherNames>Munderi P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d5e1f0de0db1.31258339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33AC9E60-EDCC-476F-AFA4-B4DCB273DBEC</gtr:id><gtr:title>Longitudinal effect of CD4 by cotrimoxazole use on malaria incidence among HIV-infected Ugandan adults on antiretroviral therapy: a randomized controlled study.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba3865702ef271ce3122cab908370961"><gtr:id>ba3865702ef271ce3122cab908370961</gtr:id><gtr:otherNames>Kasirye R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>58c66eaa299791.67502907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72F33ACE-089D-4E44-B66B-5EF9F4059C6A</gtr:id><gtr:title>Effect of antiretroviral therapy on malaria incidence in HIV-infected Ugandan adults.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77ddb32c61314a52229bd93344688de0"><gtr:id>77ddb32c61314a52229bd93344688de0</gtr:id><gtr:otherNames>Kasirye RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>58c66eaa4ea2e7.90222589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFAFE17D-3648-4D7F-9375-4037FC5663F2</gtr:id><gtr:title>Exit interviews administered to patients participating in the COSTOP placebo controlled randomised trial in Uganda.</gtr:title><gtr:parentPublicationTitle>Contemporary clinical trials communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8f618fdecf7990e35858764386f35ae"><gtr:id>e8f618fdecf7990e35858764386f35ae</gtr:id><gtr:otherNames>Nunn A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2451-8654</gtr:issn><gtr:outcomeId>58c66f88901c45.72495404</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0234692-93A3-46A1-BC70-C2076DF75C64</gtr:id><gtr:title>Effect of cotrimoxazole prophylaxis on malaria occurrence in HIV-infected patients on antiretroviral therapy in sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba3865702ef271ce3122cab908370961"><gtr:id>ba3865702ef271ce3122cab908370961</gtr:id><gtr:otherNames>Kasirye R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>56d5df9ce83f92.01350277</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_EX_UU_G0902150</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>13981021-24EA-4648-A954-C235506E2CD9</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>3.2  Interventions to alter physical and biological environmental risks</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>